Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Inv. presentation
Quarterly results
MYOGEN INC (MYOG) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/11/2012 CT ORDER Form CT ORDER - Confidential treatment order
02/14/2007 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
11/17/2006 8-K Quarterly results
11/16/2006 SC 13D/A GAMCO INVESTORS, INC. ET AL reports a 0.4% stake in Myogen, Inc.
11/13/2006 SC 13G/A FMR CORP reports a 5.6% stake in Myogen Inc.
11/06/2006 SC 13D/A GAMCO INVESTORS, INC. ET AL reports a 2.9% stake in Myogen, Inc.
11/06/2006 10-Q Quarterly Report for the period ended September 30, 2006
10/27/2006 SC 13D GAMCO INVESTORS, INC. ET AL reports a 2.4% stake in Myogen, Inc.
10/24/2006 8-K Termination of a Material Definitive Agreement
10/05/2006 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "Agreement and Plan of Merger, by and among Gilead Sciences, Inc., Mustang Merger Sub, Inc. and Myogen, Inc",
"GILEAD SCIENCES TO ACQUIRE MYOGEN, INC. FOR $2.5 BILLION"
09/25/2006 8-K Investor presentation
Docs: "Myogen, Inc. Investor and Analyst Presentation Materials"
09/18/2006 8-K Entry into a Material Definitive Agreement
09/06/2006 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]
08/09/2006 10-Q Quarterly Report for the period ended June 30, 2006
08/08/2006 8-K Quarterly results
Docs: "MYOGEN REPORTS 2006 SECOND QUARTER RESULTS"
08/03/2006 8-K Investor presentation
Docs: "Myogen, Inc. Investor and Analyst Presentation Materials"
07/11/2006 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "MYOGEN ANNOUNCES EXTENSION OF DRUG DISCOVERY COLLABORATION"
06/14/2006 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Poster entitled “Effects of Darusentan Treatment on Systolic Blood Pressure Control in Patients with Resistant Hypertension.”"
05/16/2006 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Poster entitled “Darusentan Reduces 24-hour Ambulatory Blood Pressure in Patients with Resistant Hypertension.”"
05/09/2006 10-Q Quarterly Report for the period ended March 31, 2006
05/08/2006 8-K Investor presentation
Docs: "Myogen, Inc. Investor and Analyst Presentation Materials"
05/08/2006 8-K Quarterly results
Docs: "MYOGEN REPORTS 2006 FIRST QUARTER RESULTS"
05/03/2006 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "MYOGEN REPORTS RESULTS FOR THE INTEGRATED ANALYSIS OF ARIES-1 AND ARIES-2 PIVOTAL TRIALS OF AMBRISENTAN IN"
04/11/2006 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "MYOGEN REPORTS POSITIVE TOP LINE RESULTS FOR SECOND AMBRISENTAN"
04/10/2006 SC 13G/A PRICE T ROWE ASSOCIATES INC reports a 11.3% stake in Myogen, Inc.
04/10/2006 SC 13G FMR CORP reports a 11.8% stake in Myogen Inc.
04/07/2006 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/05/2006 8-K Regulation FD Disclosure
03/15/2006 10-K Annual Report for the period ended December 31, 2005
03/07/2006 8-K Investor presentation
Docs: "Myogen, Inc. Investor and Analyst Presentation Materials"
03/06/2006 8-K Asset disposition
Docs: "GlaxoSmithKline And Myogen Announce Pulmonary Arterial Hypertension Partnership GlaxoSmithKline to Commercialise Ambrisentan in All Territories Outside of the U.S. Myogen Receives Flolan Rights in U.S. and Will Launch Commercial Operations in Q2'06",
"MYOGEN REPORTS 2005 RESULTS"
02/27/2006 8-K Entry into a Material Definitive Agreement, Departure of Directors or Principal Officers; Election of Directors; Appointment ...
02/14/2006 SC 13G/A HBK INVESTMENTS L P reports a 12% stake in MYOGEN INC.
02/14/2006 SC 13G/A CVCA, LLC reports a 0% stake in Myogen, Inc.
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy